Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Our aim is to understand fundamental biological processes that could inform the development of targeted therapies and innovative biomarkers in neurodegenerative and neurogenetic disorders.

We are investigating disease mechanisms at different levels
We are investigating disease mechanisms at different levels

The group was established by Dr Tofaris to investigate cellular mechanisms that regulate the clearance of misfolded proteins or damaged organelles in age-related neurodegenerative and rare neurogenetic disorders with a primary focus on Parkinson’s disease. To this end, we are currently employing a multifaceted approach encompassing forward genetics, proteomics and transcriptomics in models of increasing cellular complexity, including the use of patient-derived induced pluripotent stem cells (iPSC) to:

  • Identify enzymes that are relevant to alpha-synuclein homeostasis or dopaminergic cell viability more broadly
  • Understand how disruption of these mechanisms leads to disease
  • Translate this fundamental knowledge into rational mechanism-based therapies

In collaboration with the Department of Chemistry in Oxford, we are also investigating the role of exosomes as biomarkers of Parkinson’s disease progression. 

Our work involves interactions with research groups internationally via the EU IMI Consortium IMPRiND and the pharmaceutical industry.

Funders

Wellcome logo BMA
EPSRC ARUK
Oxford BRC EU IMI logo
wbi.png

 

 

 

 

Selected publications

Related research themes